RePORT ⟩ RePORTER

Project Details

NIAID- VRC- Research, Development, and Production to Support Clinical Trials for HIV Vaccines.

Project Number75N91019D00024-P00001-759102200006-1

Contact PI/Project LeaderLINDSAY, DAVID

Awardee OrganizationLEIDOS BIOMEDICAL RESEARCH, INC.

Description

Abstract Text

The Dale and Betty Bumpers Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), at the National Institutes of Health, was established to facilitate research in vaccine development and is dedicated to improving global human health through the rigorous pursuit of effective vaccines and treatments for human diseases. One of the key components of the VRC's mission involves the rapid advancement of promising candidates from the laboratory to the clinic. Meeting this mission necessitates the development and manufacturing of vaccines for toxicology, and Phase 1/11 clinical trials.

Public Health Relevance Statement

Data not available.

NIH Spending Category

BiotechnologyClinical ResearchClinical Trials and Supportive ActivitiesHIV/AIDSImmunizationInfectious DiseasesPreventionVaccine RelatedVaccine Related (AIDS)

Project Terms

Biological AssayClinicClinical TrialsDevelopmentHIV vaccineHealthHumanLaboratoriesMissionNational Institute of Allergy and Infectious DiseasePhaseProductionResearchTestingToxicologyUnited States National Institutes of HealthVaccine ResearchVaccineshuman diseaseimprovedlarge scale productionmanufacturing processmeetingsresearch and developmentvaccine development

Details

Contact PI/ Project Leader

Name

LINDSAY, DAVID

Title

Contact

Other PIs

Not Applicable

Program Official

Name

Contact

Email not available

Organization

Name

LEIDOS BIOMEDICAL RESEARCH, INC.

City

FREDERICK

Country

UNITED STATES (US)

Department Type

Unavailable

Organization Type

Domestic For-Profits

State Code

Congressional District

Other Information

Opportunity Number

Study Section

Fiscal Year

2022

Award Notice Date

Administering Institutes or Centers

National Institute of Allergy and Infectious Diseases

CFDA Code

DUNS Number

159990456

UEI

HV8BH9BPG8Y9

Project Start Date

12-April-2022

Project End Date

17-July-2027

Budget Start Date

Budget End Date

Project Funding Information for 2022

Total Funding

$10,143,220

Direct Costs

Indirect Costs

Year	Funding IC	FY Total Cost by IC
2022	National Institute of Allergy and Infectious Diseases	$10,143,220

NIH Categorical SpendingClick here for more information on NIH Categorical Spending

Funding IC	FY Total Cost by IC	NIH Spending Category
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES	$10,143,220	Biotechnology; Clinical Research; Clinical Trials and Supportive Activities; HIV/AIDS; Immunization; Infectious Diseases; Prevention; Vaccine Related; Vaccine Related (AIDS)

Sub Projects

No Sub Projects information available for 75N91019D00024-P00001-759102200006-1

Publications

Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.

No Publications available for 75N91019D00024-P00001-759102200006-1

Patents

No Patents information available for 75N91019D00024-P00001-759102200006-1

Outcomes

The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.

No Outcomes available for 75N91019D00024-P00001-759102200006-1

Clinical Studies

No Clinical Studies information available for 75N91019D00024-P00001-759102200006-1

News and More

Section Menu